A Phase 1/2 interventional study of Olvi-Vec and Platinum-doublet with or without bevacizumab in Ovarian Cancer, Peritoneal Carcinomatosis and Fallopian Tube Cancer, sponsored by Genelux Corporation. Completed at 2 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Genelux Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.
Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 751st largest by enrollment of the 1,498 interventional ones that give a count, is one of 72 that started in 2016, is one of 222 in phase 1/2, and was the 966th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Israel, Taiwan
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+
GE Healthcare · Sites in United States, Sweden
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 21 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,779 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 769 · Phase 2 718 · Phase 3 114 · Phase 4 8
First in 1980; this study’s year is marked. 72 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 1,498 interventional studies, 176 across the 195 observational. Of the 1,209 that completed or were terminated, 445 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
713 of 1,779 have an industry lead sponsor. The 10 most frequent:
Genelux Corporation is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Genelux Corporation has 2 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
162 of the studies in Ovarian Neoplasms with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05281471Phase 3Genelux CorporationEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | 2026-12 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
Add all 162 to your calendar (.ics) → With an account.
Among the 1,779 studies in Ovarian Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, Olvi-Vec, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than 30 different human tumors, including ovarian cancer. Olvi-Vec has been investigated in early stage clinical trials in the United States and Europe via systemic delivery as monotherapy and in combination with other therapies, and via regional delivery as monotherapy. Olvi-Vec treatment was well tolerated across different malignancies, routes of administration, and monotherapy as well as combination therapy protocols. The ability of Olvi-Vec to infect tumor tissue and kill tumor cells was demonstrated. In addition, virus-induced immune activation and favorable anti-tumor immune response have been observed. Evidences of anti-tumor efficacy and clinical benefits have also been documented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated in Cohort 1 received 2 IP infusions at 3 x 10e9 pfu.
Biological: Olvi-Vec
Participants treated in Cohort 2 received 2 IP infusions at 1 x 10e10 pfu.
Biological: Olvi-Vec
Participants treated in Cohort 3 received 2 IP infusions at 2.5 x 10e10 pfu.
Biological: Olvi-Vec
Participants treated in the Phase 2 portion received 2 IP infusions of Olvi-Vec at 3 x 10e9 pfu followed by platinum-doublet chemotherapy with or without bevacizumab.
Biological: Olvi-Vec · Drug: Platinum-doublet with or without bevacizumab
Olvi-Vec is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
Also known as: Olvimulogene nanivacirepvec
Drug page: Bevacizumab
Carboplatin + choice of non-platinum chemotherapy drug: taxane, paclitaxel, nab-paclitaxel, gemcitabine or doxorubicin pegylated liposomal with or without bevacizumab.
Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b)
Determine safety and tolerability of administering 2 consecutive doses of Olvi-Vec via intraperitoneal catheter by the evaluation of the number of participants with related treatment-emergent adverse events (type, frequency, and severity) as assessed by CTCAE 4.03.
Time frame: Change from baseline during Treatment and for 30 days following last dose over average of 2 years.
Progression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: For participants enrolled in the Phase 2 portion, outcome is from the date of starting chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Overall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer
To assess anti-tumor response by Overall Response Rate by Tumor Marker Cancer Antigen-125 (CA-125) for participants who were enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer.
Time frame: Assessed pre-treatment, during treatment at 2- to 3-week intervals and post-treatment assessed up to 24 months.
Overall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer
To assess anti-tumor response by Overall Response Rate (ORR) defined as disease control rate (DCR = CR + PR + SD≥15 weeks) by RECIST 1.1 criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.
Time frame: For evaluable participants enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer who were assessed at pre-treatment, during treatment at 6- to 12-week intervals and post-treatment up to 24 months.
Evaluation of Tumor Response to Treatment for Participants Enrolled in the Phase 1b Portion of This Study
Participants enrolled in the Phase 1b study were assessed for best overall response to treatment with therapeutic intent by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.
Time frame: Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.
CA-125 Response in Participants Enrolled in the Phase 1b Portion of This Study
CA-125 according to the Gynecologic Cancer Intergroup (GCIG) is measured by at least a 50% reduction in CA-125 levels from pre-treatment sample which is confirmed and maintained for at least 28 days. Pre-treatment CA-125 sample must be at least twice the upper limit of normal and obtained within 2 weeks prior to starting treatment.
Time frame: Assessed pre-treatment, during treatment and post-treatment at 6 to 12 week intervals, assessed up to 24 months.
Determine Progression-free Survival Following Treatment (Phase 1b)
To assess the number of months of progression-free survival (PFS) by RECIST 1.1.
Time frame: From the date of starting chemotherapy until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Overall Survival
To determine overall survival (OS) in the participant population.
Time frame: By medical chart review until death or 3 years from the date of last treatment whichever comes first.
Clinical Benefit Rate
Defined as the percentage of patients who have achieved CR + PR + SD by RECIST 1.1.
Time frame: Approximately 24 months
Evaluation of Immune-related Tumor Response
This exploratory outcome measure evaluates participants' best overall response to treatment with oncolytic immunotherapy assessed by Immune-related Response Criteria (immune-related complete response, immune-related partial response, immune-related stable disease, or immune-related progressive disease).
Time frame: Assessed post-treatment at 6 to 12 week intervals or until disease progression or death from any cause, whichever comes first, assessed up to 24 months.
Participants were enrolled at 2 clinical sites in the United States. Enrollment into cohorts based on order of consented and eligible participants into an open cohort.
| Milestone | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants |
|---|---|---|---|---|---|
| Started | 6 | 5 | 1 | 22 | 12 |
| Completed | 1 | 1 | 0 | 2 | 1 |
| Not completed | 5 | 4 | 1 | 20 | 11 |
| Withdrew: Death | 5 | 4 | 1 | 18 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 |
Determine safety and tolerability of administering 2 consecutive doses of Olvi-Vec via intraperitoneal catheter by the evaluation of the number of participants with related treatment-emergent adverse events (type, frequency, and severity) as assessed by CTCAE 4.03.
| Participants | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants |
|---|---|---|---|
| Participants with Mild, Moderate or Severe related TEAEs | 5 | 5 | 1 |
| Participants with life-threatening related TEAEs | 0 | 0 | 0 |
| Participants with related TEAEs with outcome of death | 0 | 0 | 0 |
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Number of months | Phase 2 - Cohort A Platinum-resistant Participants | Phase 2 - Cohort A Platinum-refractory Participants | Phase 2 - Cohort C Platinum-resistant Participants | Phase 2 - Cohort C Platinum-refractory Participants |
|---|---|---|---|---|
| Progression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer. | 10 (4.0 to NA) | 10.3 (4.3 to NA) | 11 (5.2 to NA) | 10.1 (1.1 to 11.5) |
To assess anti-tumor response by Overall Response Rate by Tumor Marker Cancer Antigen-125 (CA-125) for participants who were enrolled in the Phase 2 portion of this study with platinum-resistant or platinum-refractory ovarian cancer.
| Percent of participants | Phase 2 - Cohort A Platinum-resistant Participants | Phase 2 - Cohort A Platinum-refractory Participants | Phase 2 - Cohort C Platinum-resistant Participants | Phase 2 - Cohort C Platinum-refractory Participants |
|---|---|---|---|---|
| Overall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer | 80.0 | 66.7 | 75.0 | 85.7 |
To assess anti-tumor response by Overall Response Rate (ORR) defined as disease control rate (DCR = CR + PR + SD≥15 weeks) by RECIST 1.1 criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.
| Percent of participants | Phase 2 - Cohort A Platinum-resistant Participants | Phase 2 - Cohort A Platinum-refractory Participants | Phase 2 - Cohort C Platinum-resistant Participants | Phase 2 - Cohort C Platinum-refractory Participants |
|---|---|---|---|---|
| Overall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer | 87.5 | 33.3 | 33.3 | 60.0 |
Participants enrolled in the Phase 1b study were assessed for best overall response to treatment with therapeutic intent by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. criteria: Complete Response (CR) is a disappearance of all target lesions; Partial Response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to quality for progressive disease; Progressive Disease (PD) is at least a 20% increase in sum of longest diameter of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.
| Participants | Phase 1b - Cohort 1 | Phase 1b - Cohort 2 |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 1 | 1 |
| Stable Disease | 1 | 0 |
| Progressive Disease | 0 | 0 |
| Unevaluable | 0 | 0 |
CA-125 according to the Gynecologic Cancer Intergroup (GCIG) is measured by at least a 50% reduction in CA-125 levels from pre-treatment sample which is confirmed and maintained for at least 28 days. Pre-treatment CA-125 sample must be at least twice the upper limit of normal and obtained within 2 weeks prior to starting treatment.
| Participants | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants |
|---|---|---|
| CA-125 Response in Participants Enrolled in the Phase 1b Portion of This Study | 2 | 1 |
To assess the number of months of progression-free survival (PFS) by RECIST 1.1.
| Number of months | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants |
|---|---|---|
| Determine Progression-free Survival Following Treatment (Phase 1b) | 11.6 (11.6 to NA) | 16.7 (16.7 to 16.7) |
To determine overall survival (OS) in the participant population.
| Number of months | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants |
|---|---|---|---|---|
| Overall Survival | 33.6 (33.6 to NA) | 61.7 (61.7 to NA) | 18.5 (11.3 to 23.8) | 12.7 (3.2 to 15.7) |
Defined as the percentage of patients who have achieved CR + PR + SD by RECIST 1.1.
| Percent of participants | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants |
|---|---|---|---|---|
| Clinical Benefit Rate | 100 | 100 | 91 | 100 |
This exploratory outcome measure evaluates participants' best overall response to treatment with oncolytic immunotherapy assessed by Immune-related Response Criteria (immune-related complete response, immune-related partial response, immune-related stable disease, or immune-related progressive disease).
No measurements were reported for this outcome.
Collected over During GL-ONC1 treatment and until the 30-day Post-treatment for an average of 2 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b - Cohort 1 | 5/6 (83.3%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Phase 1b - Cohort 2 | 5/5 (100%) | 1/5 (20%) | 5/5 (100%) |
| Phase 1b - Cohort 3 | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Phase 2 - Cohort A | 22/22 (100%) | 5/22 (22.7%) | 22/22 (100%) |
| Phase 2 - Cohort C | 11/12 (91.7%) | 2/11 (18.2%) | 11/11 (100%) |
| Event | Phase 1b - Cohort 1 | Phase 1b - Cohort 2 | Phase 1b - Cohort 3 | Phase 2 - Cohort A | Phase 2 - Cohort C |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/6 | 1/5 | 0/1 | 0/22 | 0/11 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/5 | 0/1 | 1/22 | 0/11 |
| VomitingGastrointestinal disorders | 1/6 | 0/5 | 0/1 | 3/22 | 0/11 |
| AstheniaGeneral disorders | 1/6 | 0/5 | 0/1 | 0/22 | 0/11 |
| DehydrationMetabolism and nutrition disorders | 1/6 | 0/5 | 0/1 | 0/22 | 0/11 |
| NauseaGastrointestinal disorders | 0/6 | 0/5 | 0/1 | 0/22 | 1/11 |
| FatigueGeneral disorders | 0/6 | 0/5 | 0/1 | 0/22 | 1/11 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 0/5 | 0/1 | 1/22 | 0/11 |
| Event | Phase 1b - Cohort 1 | Phase 1b - Cohort 2 | Phase 1b - Cohort 3 | Phase 2 - Cohort A | Phase 2 - Cohort C |
|---|---|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 0/6 | 4/5 | 1/1 | 15/22 | 3/11 |
| AscitesGastrointestinal disorders | 0/6 | 2/5 | 1/1 | 1/22 | 1/11 |
| ChillsGeneral disorders | 2/6 | 5/5 | 0/1 | 5/22 | 5/11 |
| PyrexiaGeneral disorders | 2/6 | 3/5 | 0/1 | 15/22 | 8/11 |
| Abdominal painGastrointestinal disorders | 2/6 | 1/5 | 0/1 | 15/22 | 5/11 |
| NauseaGastrointestinal disorders | 4/6 | 3/5 | 0/1 | 15/22 | 2/11 |
| FatigueGeneral disorders | 2/6 | 1/5 | 0/1 | 8/22 | 4/11 |
| VomitingGastrointestinal disorders | 2/6 | 0/5 | 0/1 | 5/22 | 2/11 |
| HeadacheNervous system disorders | 2/6 | 0/5 | 0/1 | 1/22 | 2/11 |
| SomnolenceNervous system disorders | 2/6 | 0/5 | 0/1 | 0/22 | 0/11 |
Participants who received at least 1 dose of Olvi-Vec.
| Age, Categorical(Participants) | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 0 | 15 | 8 | 28 |
| >=65 years | 4 | 2 | 1 | 7 | 4 | 18 |
| Sex: Female, Male(Participants) | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 5 | 1 | 22 | 12 | 46 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 3 | 4 | 7 |
| Not Hispanic or Latino | 6 | 5 | 1 | 19 | 8 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 1 |
| White | 5 | 5 | 1 | 21 | 11 | 43 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants | Total |
|---|---|---|---|---|---|---|
| United States | 6 | 5 | 1 | 22 | 12 | 46 |
| Platinum Disease(Participants) | Phase 1b - Cohort 1 Participants | Phase 1b - Cohort 2 Participants | Phase 1b - Cohort 3 Participants | Phase 2 - Cohort A Participants | Phase 2 - Cohort C Participants | Total |
|---|---|---|---|---|---|---|
| Platinum-resistant ovarian cancer | 4 | 3 | 1 | 14 | 5 | 27 |
| Platinum-refractory ovarian cancer | 2 | 2 | 0 | 6 | 7 | 17 |
| Intermediate platinum-sensitive ovarian cancer | 0 | 0 | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of May 2016, a primary completion of Dec 2021 and a completion of Dec 2022. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2026, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olvimulogene nanivacirepvec
Genelux Corporation